-- 根據週二提交給澳洲證券交易所的文件顯示，Clinuvel Pharmaceuticals（ASX：CUV）表示，公司正與美國證券交易委員會（SEC）合作，就其美國存託憑證（ADR）項目在納斯達克股票市場上市的註冊聲明草案進行磋商。 該公司已收到美國證券交易委員會的四輪意見徵詢，預計審查流程將在本財政年度結束前完成。根據文件，該公司計劃將ADR項目從一級升級至二級，並以修訂後的股票代碼「CUVL」在納斯達克上市。 該公司在文件中補充道，此次上市仍需獲得監管機構的批准以及滿足納斯達克的相關要求，其成功與否以及上市時間均無法保證。
Related Articles
Asia
Bio Port Korea Returns to Profit in Q1
Bio Port Korea (KOSDAQ:188040) posted first-quarter net income of 710 million won, rebounding from a net loss of 34 million won a year earlier, according to a Tuesday filing with the Korea Exchange.The South Korean health functional foods company's sales revenue jumped 27% year over year to 21.4 billion won from 16.9 billion won.Shares of Bio Port Korea rose more than 2% in recent trade.
$KOSDAQ:188040
Asia
Yanghe Brewery 2025 Profit Falls 67%, Revenue Slips 33%
Jiangsu Yanghe Brewery (SHE:002304) posted 2025 attributable net profit of 2.21 billion yuan, down 67% from 6.67 billion yuan the previous year.Earnings per share fell to 1.4644 yuan from 4.4299 yuan, according to a Tuesday filing with the Shenzhen bourse.The liquor company's revenue declined 33% year over year to 19.2 billion yuan from 28.9 billion yuan.
$SHE:002304
Asia
Resolution Minerals Produces Tungsten Trioxide Concentrates Via Preliminary Gravity Separation Test Work, Shares Up 4%
Resolution Minerals (ASX:RML) produced concentrates of 52.3% tungsten trioxide via preliminary gravity separation test work on tungsten composite samples, assaying 1.85% grade of tungsten trioxide, from stockpiles at the Johnson Creek mill site, sourced from the historical mining at the Golden Gate tungsten mine in Idaho, according to a Tuesday Australian bourse filing.Heavy liquid separation scoping tests on the tungsten composite samples achieved a grade of 52.3% of tungsten trioxide with a recovery of 75.5%.Its shares rose 4% in recent trading on Tuesday.
$ASX:RML